Ralf J Ludwig

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3062879/publications.pdf

Version: 2024-02-01

256	9,235	44444	68831
papers	citations	50 h-index	81 g-index

270	270	270	8858
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Investigating the epidemiological relationship between vitiligo and psoriasis: a population-based study. Archives of Dermatological Research, 2023, 315, 395-400.	1.1	3
2	Association between TH2 Cytokine Gene Polymorphisms and Risk of Bullous Pemphigoid. Immunological Investigations, 2022, 51, 343-356.	1.0	11
3	Anxiety and depression predispose individuals to an autoimmune bullous diseases- bullous pemphigoid: A large-scale population-based cohort study. Current Psychology, 2022, 41, 8945-8955.	1.7	6
4	Melanoma is associated with an increased risk of bullous pemphigoid: a large population-based longitudinal study. Archives of Dermatological Research, 2022, 314, 77-83.	1.1	6
5	Pathogenic Autoantibody Derived from Regulatory T Cellâ€'Deficient Scurfy Mice Targets Type VII Collagen and Leads to Epidermolysis Bullosa Acquisitaâ€'Like Blistering Disease. Journal of Investigative Dermatology, 2022, 142, 980-984.e4.	0.3	1
6	Evidence for a role of extracellular heat shock protein 70 in epidermolysis bullosa acquisita. Experimental Dermatology, 2022, 31, 528-534.	1.4	4
7	Natural Occurrence of Autoantibodies against Basement Membrane Proteins in Epidermolysis Bullosa. Journal of Investigative Dermatology, 2022, 142, 2014-2019.e3.	0.3	4
8	Evaluation of Site- and Autoantigen-Specific Characteristics of Mucous Membrane Pemphigoid. JAMA Dermatology, 2022, 158, 84.	2.0	22
9	C5aR2 Deficiency Ameliorates Inflammation inÂMurine Epidermolysis Bullosa Acquisita by Regulating FcÎ³ Receptor Expression on Neutrophils. Journal of Investigative Dermatology, 2022, 142, 2715-2723.e2.	0.3	7
10	Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris. Acta Dermato-Venereologica, 2022, 102, adv00679.	0.6	1
11	Pathological Relevance of Anti-Hsp70 IgG Autoantibodies in Epidermolysis Bullosa Acquisita. Frontiers in Immunology, 2022, 13, 877958.	2.2	3
12	Biodiversity of mycobial communities in health and onychomycosis. Scientific Reports, 2022, 12, .	1.6	3
13	Challenge of hepatitis B testing following intravenous immunoglobulin therapy in patients with autoimmune skinÂdiseases. Journal of Dermatology, 2022, 49, 1049-1051.	0.6	3
14	Distinct metabolite profile in pemphigus vulgaris. Journal of Investigative Dermatology, 2022, , .	0.3	0
15	IgG Fc N-Glycosylation Translates MHCII Haplotype into Autoimmune Skin Disease. Journal of Investigative Dermatology, 2021, 141, 285-294.	0.3	12
16	More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study. American Journal of Clinical Dermatology, 2021, 22, 117-127.	3.3	12
17	Immunoglobulin M pemphigoid. Journal of the American Academy of Dermatology, 2021, 85, 1486-1492.	0.6	16
18	Granzyme B inhibition reduces disease severity in autoimmune blistering diseases. Nature Communications, 2021, 12, 302.	5.8	49

#	Article	IF	Citations
19	A Mitochondrial Polymorphism Alters Immune Cell Metabolism and Protects Mice from Skin Inflammation. International Journal of Molecular Sciences, 2021, 22, 1006.	1.8	17
20	Therapeutic Implications of Targeting Heat Shock Protein 70 by Immunization or Antibodies in Experimental Skin Inflammation. Frontiers in Immunology, 2021, 12, 614320.	2.2	9
21	A History of Asthma Increases the Risk of Bullous Pemphigoid: Insights from a Large Population-Based Study. Dermatology, 2021, 237, 921-928.	0.9	5
22	Editorial: Skin Autoimmunity. Frontiers in Immunology, 2021, 12, 627565.	2.2	1
23	The G proteinâ€coupled receptor 15 (GPR15) regulates cutaneous immunology by maintaining dendritic epidermal T cells and regulating the skin microbiome. European Journal of Immunology, 2021, 51, 1390-1398.	1.6	4
24	Prevalence and presumptive triggers of localized bullous pemphigoid. Journal of Dermatology, 2021, 48, 1257-1261.	0.6	10
25	Immunological features and factors associated with mucocutaneous bullous pemphigoid â€“ a retrospective cohort study. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1289-1295.	0.4	10
26	The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: AÂpopulation-based cohort study. Journal of the American Academy of Dermatology, 2021, 85, 79-87.	0.6	15
27	Pathogenic Activation and Therapeutic Blockage of FcÎ±R-Expressing Polymorphonuclear Leukocytes in IgA Pemphigus. Journal of Investigative Dermatology, 2021, 141, 2820-2828.	0.3	5
28	Editorial: Precision Medicine in Chronic Inflammation. Frontiers in Immunology, 2021, 12, 770462.	2.2	7
29	Topical Application of the PI3KÎ²-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita. Frontiers in Medicine, 2021, 8, 713312.	1.2	5
30	Estimating the Odds of Ulcerative Colitis-Associated Pyoderma Gangrenosum: A Population-Based Case-Control Study. Dermatology, 2021, 237, 323-329.	0.9	3
31	Preventive but Not Therapeutic Topical Application of Local Anesthetics Can Inhibit Experimental Epidermolysis Bullosa Acquisita in Mice. Frontiers in Immunology, 2021, 12, 750160.	2.2	3
32	Lichen Planus. Frontiers in Medicine, 2021, 8, 737813.	1.2	36
33	Risk of solid malignancies in bullous pemphigoid: A largeâ€scale populationâ€based cohort study. Journal of Dermatology, 2021, 48, 317-323.	0.6	5
34	Retrospective analysis of the clinical characteristics and patientâ€reported outcomes in vulval lichen planus: Results from a singleâ€center study. Journal of Dermatology, 2021, 48, 1913-1917.	0.6	9
35	Immunization with desmoglein 3 induces non-pathogenic autoantibodies in mice. PLoS ONE, 2021, 16, e0259586.	1.1	2
36	Multiple modes of action mediate the therapeutic effect of IVIg in experimental epidermolysis bullosa acquisita. Journal of Investigative Dermatology, 2021, , .	0.3	4

#	Article	IF	Citations
37	The MCPâ€1 rs1024611 and MTHFR rs1801133 gene variations and expressions in alopecia areata: A pilot study. Immunity, Inflammation and Disease, 2021, , .	1.3	2
38	Tissueâ€specific personalized medicine: the next level of individualized treatment. British Journal of Dermatology, 2020, 182, 833-834.	1.4	0
39	Assessment of healthcare costs for patients with pemphigus and bullous pemphigoid in an academic centre in Germany. British Journal of Dermatology, 2020, 182, 1296-1297.	1.4	14
40	The Bidirectional Association Between Bullous Pemphigoid and Psoriasis: A Population-Based Cohort Study. Frontiers in Medicine, 2020, 7, 511.	1.2	24
41	Quantification of the relationship between pyoderma gangrenosum and Crohnâ€™s disease: a population-based case-control study. Scandinavian Journal of Gastroenterology, 2020, 55, 814-818.	0.6	4
42	Phenotyping of Adaptive Immune Responses in Inflammatory Diseases. Frontiers in Immunology, 2020, 11, 604464.	2.2	6
43	COVIDâ€19 and immunological regulations â€“ from basic and translational aspects to clinical implications. JDDG - Journal of the German Society of Dermatology, 2020, 18, 795-807.	0.4	45
44	Alterations of Total Serum Immunoglobulin Concentrations in Pemphigus and Pemphigoid: Selected IgG2 Deficiency in Bullous Pemphigoid. Frontiers in Medicine, 2020, 7, 472.	1.2	5
45	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1900-1913.	1.3	159
46	Identification of novel therapeutic targets for blocking acantholysis in pemphigus. British Journal of Pharmacology, 2020, 177, 5114-5130.	2.7	20
47	Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series. Frontiers in Medicine, 2020, 7, 543944.	1.2	13
48	IL12B and IL23R polymorphisms are associated with alopecia areata. Genes and Immunity, 2020, 21, 203-210.	2.2	16
49	Dupilumab for treatmentâ€refractory prurigo nodularis. JDDG - Journal of the German Society of Dermatology, 2020, 18, 618-624.	0.4	12
50	Penile mucous membrane pemphigoid. JDDG - Journal of the German Society of Dermatology, 2020, 18, 727-729.	0.4	3
51	Low prevalence of late-onset neutropenia after rituximab treatment in patients with pemphigus. Journal of the American Academy of Dermatology, 2020, 83, 1824-1825.	0.6	3
52	Is Gout Associated with Pyoderma Gangrenosum? A Population-Based Case-Control Study. Journal of Clinical Medicine, 2020, 9, 1626.	1.0	7
53	Epidermal Damage Induces Th1 Polarization and Defines the Site of Inflammation in Murine Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2020, 140, 1713-1722.e9.	0.3	6
54	Visualization of autoantibodies and neutrophils in vivo identifies novel checkpoints in autoantibody-induced tissue injury. Scientific Reports, 2020, 10, 4509.	1.6	9

#	Article	IF	Citations
55	Impact of diet and genes on murine autoimmune pancreatitis. Journal of Cellular and Molecular Medicine, 2020, 24, 8862-8870.	1.6	8
56	Serum Levels of Autoantibodies Against Extracellular Antigens and Neutrophil Granule Proteins Increase in Patients with COPD Compared to Non-COPD Smokers . International Journal of COPD, 2020, Volume 15, 189-200.	0.9	8
57	Treatment with antiâ€neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice. British Journal of Pharmacology, 2020, 177, 2381-2392.	2.7	20
58	Milestones in Personalized Medicine in Pemphigus and Pemphigoid. Frontiers in Immunology, 2020, 11, 591971.	2.2	17
59	Propranolol Is an Effective Topical and Systemic Treatment Option for Experimental Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2020, 140, 2408-2420.	0.3	7
60	Drug Development in Pemphigoid Diseases. Acta Dermato-Venereologica, 2020, 100, adv00055-114.	0.6	10
61	Increased Risk of Pemphigus among Patients with Psoriasis: A Large-scale Cohort Study. Acta Dermato-Venereologica, 2020, 100, adv00293.	0.6	12
62	Presence of Cutaneous Complement Deposition Distinguishes between Immunological and Histological Features of Bullous Pemphigoidâ€"Insights from a Retrospective Cohort Study. Journal of Clinical Medicine, 2020, 9, 3928.	1.0	7
63	TH17/IL23 cytokine gene polymorphisms in bullous pemphigoid. Molecular Genetics & Genomic Medicine, 2020, 8, e1519.	0.6	6
64	Overlapping and Distinct Gene Polymorphisms in Alopecia Areata in an Iranian Population. Immunological Investigations, 2020, 49, 204-214.	1.0	3
65	075 Inhibition of phosphodiesterase-4 significantly decreases oral mucosa lesions in experimental anti-laminin 332 mucous membrane pemphigoid. Journal of Investigative Dermatology, 2019, 139, S227.	0.3	0
66	372 Inhibition of phosphatidylinositol-3-kinase Î´ improves tissue destruction in pemphigoid diseases by impairing neutrophil function. Journal of Investigative Dermatology, 2019, 139, S278.	0.3	0
67	Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line. Nature Communications, 2019, 10, 4097.	5.8	35
68	The Sphingosine-1-Phosphate Receptor Modulator Fingolimod Aggravates Murine Epidermolysis BullosaÂAcquisita. Journal of Investigative Dermatology, 2019, 139, 2381-2384.e3.	0.3	15
69	Current Clinical Trials in Pemphigus and Pemphigoid. Frontiers in Immunology, 2019, 10, 978.	2.2	63
70	Proinflammatory Cytokine Gene Polymorphisms in Bullous Pemphigoid. Frontiers in Immunology, 2019, 10, 636.	2.2	10
71	Type VII collagen IgE autoantibodies in epidermolysis bullosa acquisita: more common than suspected. British Journal of Dermatology, 2019, 180, 981-983.	1.4	1
72	Bullous pemphigoid: more than one disease?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 459-460.	1.3	3

#	Article	IF	Citations
73	Drug Discovery for Pemphigoid Diseases. Current Protocols in Pharmacology, 2019, 84, e55.	4.0	24
74	Translational Use of a Standardized Full Human Skin Organ Culture Model in Autoimmune Blistering Diseases. Current Protocols in Pharmacology, 2019, 85, e56.	4.0	11
75	Editorial: Autoantibodies. Frontiers in Immunology, 2019, 10, 484.	2.2	3
76	Editorial: Skin Blistering Diseases. Frontiers in Medicine, 2019, 6, 60.	1.2	1
77	IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. Journal of Autoimmunity, 2019, 96, 104-112.	3.0	85
78	FcÎ³ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita. Frontiers in Immunology, 2019, 10, 3012.	2.2	9
79	The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies. Journal of Investigative Dermatology, 2018, 138, 458-461.	0.3	38
80	Calcitriol Treatment Ameliorates Inflammation and Blistering in Mouse Models of Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2018, 138, 301-309.	0.3	20
81	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. Frontiers in Medicine, 2018, 5, 306.	1.2	27
82	The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. Frontiers in Medicine, 2018, 5, 220.	1.2	147
83	Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet Journal of Rare Diseases, 2018, 13, 153.	1.2	64
84	Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. Journal of Allergy and Clinical Immunology, 2018, 142, 1831-1842.e7.	1.5	77
85	Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase Î´ Inhibitor in Experimental Epidermolysis Bullosa Acquisita. Frontiers in Immunology, 2018, 9, 1558.	2.2	30
86	Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita. Frontiers in Immunology, 2018, 9, 249.	2.2	31
87	Targeting IgE Antibodies by Immunoadsorption in Atopic Dermatitis. Frontiers in Immunology, 2018, 9, 254.	2.2	28
88	Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3. Frontiers in Immunology, 2018, 9, 428.	2.2	13
89	Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2. Frontiers in Immunology, 2018, 9, 488.	2.2	46
90	Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice. Frontiers in Immunology, 2018, 9, 535.	2.2	29

#	Article	IF	Citations
91	Induction of Hypergammaglobulinemia and Autoantibodies by Salmonella Infection in MyD88-Deficient Mice. Frontiers in Immunology, 2018, 9, 1384.	2.2	8
92	IgE-Selective Immunoadsorption for Severe Atopic Dermatitis. Frontiers in Medicine, 2018, 5, 27.	1.2	10
93	TNF-Î± -308G/A gene polymorphism in bullous pemphigoid and alopecia areata. Human Antibodies, 2018, 26, 201-207.	0.6	8
94	Epidermolysis Bullosa Acquisita: The 2019 Update. Frontiers in Medicine, 2018, 5, 362.	1.2	91
95	Genetic variant association of PTPN22, CTLA4, IL2RA, as well as HLA frequencies in susceptibility to alopecia areata. Immunological Investigations, 2018, 47, 666-679.	1.0	15
96	The Leukotriene B4 and its Receptor BLT1ÂActÂas Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2017, 137, 1104-1113.	0.3	73
97	Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita. Experimental Dermatology, 2017, 26, 1179-1186.	1.4	28
98	Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. Experimental Dermatology, 2017, 26, 1248-1252.	1.4	29
99	Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. Journal of Investigative Dermatology, 2017, 137, 1199-1203.	0.3	34
100	Nadroparin carries a potentially high risk of inducing cutaneous delayedâ€type hypersensitivity responses. Contact Dermatitis, 2017, 77, 35-41.	0.8	5
101	Nanoparticles prepared from porcine cells support the healing of cutaneous inflammation in mice and wound reâ€epithelialization in human skin. Experimental Dermatology, 2017, 26, 1199-1206.	1.4	4
102	Increased TREM-1 expression in inflamed skin has no functional impact on the pathogenesis of cutaneous disorders. Journal of Dermatological Science, 2017, 88, 152-155.	1.0	2
103	CCL3/MIP1Î± represents a biomarker but not a mandatory cytokine for disease development in experimental epidermolysis bullosa acquisita. Journal of Dermatological Science, 2017, 88, 248-250.	1.0	1
104	New insights into pemphigoid diseases. Experimental Dermatology, 2017, 26, 1151-1153.	1.4	1
105	In vivo enzymatic modulation of IgG antibodies prevents immune complexâ€dependent skin injury. Experimental Dermatology, 2017, 26, 691-696.	1.4	15
106	Clinical features and diagnosis of epidermolysis bullosa acquisita. Expert Review of Clinical Immunology, 2017, 13, 157-169.	1.3	68
107	Topically Applied Hsp90 Blocker 17AAG Inhibits Autoantibody-Mediated Blister-Inducing Cutaneous Inflammation. Journal of Investigative Dermatology, 2017, 137, 341-349.	0.3	25
108	The genetic difference between C57Bl/6J and C57Bl/6N mice significantly impacts Aldaraâ„¢â€induced psoriasiform dermatitis. Experimental Dermatology, 2017, 26, 349-351.	1.4	18

#	Article	IF	Citations
109	Evidence for a contributory role of a xenogeneic immune response in experimental epidermolysis bullosa acquisita. Experimental Dermatology, 2017, 26, 1207-1213.	1.4	19
110	Mechanisms of Autoantibody-Induced Pathology. Frontiers in Immunology, 2017, 8, 603.	2.2	377
111	Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases. Frontiers in Immunology, 2017, 8, 1628.	2.2	51
112	Gene Expression Analysis Reveals Novel Shared Gene Signatures and Candidate Molecular Mechanisms between Pemphigus and Systemic Lupus Erythematosus in CD4+ T Cells. Frontiers in Immunology, 2017, 8, 1992.	2.2	56
113	Reduced Skin Blistering in Experimental Epidermolysis Bullosa Acquisita After Anti-TNF Treatment. Molecular Medicine, 2016, 22, 918-926.	1.9	41
114	Cytoskeletal Regulation of Inflammation and Its Impact on Skin Blistering Disease Epidermolysis Bullosa Acquisita. International Journal of Molecular Sciences, 2016, 17, 1116.	1.8	14
115	Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e191-e192.	1.3	42
116	T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita. Scientific Reports, 2016, 6, 38357.	1.6	54
117	Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options. Journal of Investigative Dermatology, 2016, 136, 24-33.	0.3	94
118	235 Topically applied heat shock protein 90 blocker 17AAG inhibits autoantibody-mediated blister-inducing cutaneous inflammation. Journal of Investigative Dermatology, 2016, 136, S201.	0.3	0
119	In Vivo Expansion of Endogenous Regulatory T Cell Populations Induces Long-Term Suppression of Contact Hypersensitivity. Journal of Immunology, 2016, 197, 1567-1576.	0.4	19
120	PDE4 Inhibition as Potential Treatment ofÂEpidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2016, 136, 2211-2220.	0.3	23
121	Dissecting genetics of cutaneous miRNA in a mouse model of an autoimmune blistering disease. BMC Genomics, 2016, 17, 112.	1.2	8
122	IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. Journal of Allergy and Clinical Immunology, 2016, 137, 1487-1497.e6.	1.5	57
123	Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid. Journal of Dermatological Science, 2016, 81, 165-172.	1.0	3
124	Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita. Expert Opinion on Therapeutic Targets, 2016, 20, 985-998.	1.5	16
125	Skin microbiota-associated inflammation precedes autoantibody induced tissue damage in experimental epidermolysis bullosa acquisita. Journal of Autoimmunity, 2016, 68, 14-22.	3.0	25
126	Dimethylfumarate Impairs Neutrophil Functions. Journal of Investigative Dermatology, 2016, 136, 117-126.	0.3	70

#	Article	IF	Citations
127	Heat shock protein 90 is required for ex vivo neutrophilâ€driven autoantibodyâ€induced tissue damage in experimental epidermolysis bullosa acquisita. Experimental Dermatology, 2015, 24, 471-473.	1.4	23
128	Conditional depletion of mast cells has no impact on the severity of experimental epidermolysis bullosa acquisita. European Journal of Immunology, 2015, 45, 1462-1470.	1.6	27
129	Prevalence of pemphigus and pemphigoid autoantibodies in the general population. Orphanet Journal of Rare Diseases, 2015, 10, 63.	1.2	46
130	The retinoidâ€related orphan receptor alpha is essential for the endâ€stage effector phase of experimental epidermolysis bullosa acquisita. Journal of Pathology, 2015, 237, 111-122.	2.1	23
131	A recombinant fusion protein derived from dog hookworm inhibits autoantibodyâ€induced dermalâ€“epidermal separation exÂvivo. Experimental Dermatology, 2015, 24, 872-878.	1.4	5
132	Pathogenesis of Epidermolysis Bullosa Acquisita. , 2015, , 121-130.		0
133	Effects of Intravenous Immunoglobulins on Mice with Experimental Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2015, 135, 768-775.	0.3	30
134	Recombinant Soluble CD32 Suppresses Disease Progression in Experimental Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2015, 135, 916-919.	0.3	24
135	Autoantibodies to Multiple Epitopes on the Non-Collagenous-1 Domain of Type VII Collagen Induce Blisters. Journal of Investigative Dermatology, 2015, 135, 1565-1573.	0.3	23
136	Tolerance of Fondaparinux inÂImmediate-type Hypersensitivity to Heparins. American Journal of Medicine, 2015, 128, e21-e22.	0.6	3
137	Caspase-1â€“Independent IL-1 Release Mediates Blister Formation in Autoantibody-Induced Tissue Injury through Modulation of Endothelial Adhesion Molecules. Journal of Immunology, 2015, 194, 3656-3663.	0.4	44
138	Radiosensitive Hematopoietic Cells Determine the Extent of Skin Inflammation in Experimental Epidermolysis Bullosa Acquisita. Journal of Immunology, 2015, 195, 1945-1954.	0.4	30
139	Allelic and copy-number variations of FcÎ³Rs affect granulocyte function and susceptibility for autoimmune blistering diseases. Journal of Autoimmunity, 2015, 61, 36-44.	3.0	32
140	Immune mechanismâ€“targeted treatment of experimental epidermolysis bullosa acquisita. Expert Review of Clinical Immunology, 2015, 11, 1365-1378.	1.3	4
141	Animal Models to Investigate Pathomechanisms and Evaluate Novel Treatments for Autoimmune Bullous Dermatoses. Current Pharmaceutical Design, 2015, 21, 2422-2439.	0.9	19
142	Recombinant Human IgA1 and IgA2 Autoantibodies to Type VII Collagen Induce Subepidermal Blistering Ex Vivo. Journal of Immunology, 2014, 193, 1600-1608.	0.4	25
143	ptRNApred: computational identification and classification of post-transcriptional RNA. Nucleic Acids Research, 2014, 42, e167-e167.	6.5	6
144	Flightless I overâ€expression impairs skin barrier development, function and recovery following skin blistering. Journal of Pathology, 2014, 232, 541-552.	2.1	28

#	Article	IF	Citations
145	Activated CD4⁺ T cells enter the splenic Tâ€cell zone and induce autoantibodyâ€producing germinal centers through bystander activation. European Journal of Immunology, 2014, 44, 93-102.	1.6	25
146	From bedside to bench â€“ reverse translational medicine. Scientific lessons from revertant mosaicism in â€˜knockoutâ€™ humans. Experimental Dermatology, 2014, 23, 549-550.	1.4	2
147	Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses. Experimental Dermatology, 2014, 23, 585-590.	1.4	33
148	Broad requirement for terminal sialic acid residues and FcÎ³RIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. European Journal of Immunology, 2014, 44, 1444-1453.	1.6	115
149	Coâ€occurrence of autoantibodies in healthy blood donors. Experimental Dermatology, 2014, 23, 519-521.	1.4	32
150	FcÎ³ Receptors III and IV Mediate Tissue Destruction in a Novel Adult Mouse Model of Bullous Pemphigoid. American Journal of Pathology, 2014, 184, 2185-2196.	1.9	66
151	GM-CSF Modulates Autoantibody Production and Skin Blistering in Experimental Epidermolysis Bullosa Acquisita. Journal of Immunology, 2014, 192, 559-571.	0.4	37
152	Metabolite analysis distinguishes between mice with epidermolysis bullosa acquisita and healthy mice. Orphanet Journal of Rare Diseases, 2013, 8, 93.	1.2	7
153	Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. Journal of Autoimmunity, 2013, 40, 74-85.	3.0	48
154	High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy. Journal of Allergy and Clinical Immunology, 2013, 132, 131-139.	1.5	35
155	Vitamin D status in patients with bullous pemphigoid. British Journal of Dermatology, 2013, 168, 873-874.	1.4	14
156	Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease. Experimental Dermatology, 2013, 22, 552-553.	1.4	37
157	Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. Journal of the American Academy of Dermatology, 2013, 68, e89-e95.	0.6	95
158	Emerging treatments for pemphigoid diseases. Trends in Molecular Medicine, 2013, 19, 501-512.	3.5	48
159	B Cells, Dendritic Cells, and Macrophages Are Required To Induce an Autoreactive CD4 Helper T Cell Response in Experimental Epidermolysis Bullosa Acquisita. Journal of Immunology, 2013, 191, 2978-2988.	0.4	55
160	Topically Applied Flightless I Neutralizing Antibodies Improve Healing of Blistered Skin in a Murine Model of Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2013, 133, 1008-1016.	0.3	54
161	Methylprednisolone Blocks Autoantibody-Induced Tissue Damage in Experimental Models of Bullous Pemphigoid and Epidermolysis Bullosa Acquisita through Inhibition of Neutrophil Activation. Journal of Investigative Dermatology, 2013, 133, 2390-2399.	0.3	47
162	Clinical Presentation, Pathogenesis, Diagnosis, and Treatment of Epidermolysis Bullosa Acquisita. ISRN Dermatology, 2013, 2013, 1-25.	1.9	80

#	Article	IF	Citations
163	The immune system of mouse vibrissae follicles: cellular composition and indications of immune privilege. Experimental Dermatology, 2013, 22, 593-598.	1.4	17
164	Aberrant Expression and Secretion of Heat Shock Protein 90 in Patients with Bullous Pemphigoid. PLoS ONE, 2013, 8, e70496.	1.1	40
165	Persistent Autoantibody-Production by Intermediates between Short-and Long-Lived Plasma Cells in Inflamed Lymph Nodes of Experimental Epidermolysis Bullosa Acquisita. PLoS ONE, 2013, 8, e83631.	1.1	26
166	Identification of Quantitative Trait Loci in Experimental Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2012, 132, 1409-1415.	0.3	35
167	Heparin-induced skin lesions. Lancet, The, 2012, 380, 1867-1879.	6.3	82
168	Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen. Journal of Autoimmunity, 2012, 39, 304-314.	3.0	54
169	Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcÎ³RIIB and dectin-1. Nature Medicine, 2012, 18, 1401-1406.	15.2	405
170	Application, tolerance and safety of fondaparinux therapy in a German hospital: A prospective single-centre experience. Thrombosis Research, 2012, 129, 17-21.	0.8	11
171	Model systems duplicating epidermolysis bullosa acquisita: A methodological review. Autoimmunity, 2012, 45, 102-110.	1.2	16
172	Mapping of B cell epitopes on desmoglein 3 in pemphigus vulgaris patients by the use of overlapping peptides. Journal of Dermatological Science, 2012, 65, 102-109.	1.0	14
173	Genetic identification and functional validation of FcÎ³RIV as key molecule in autoantibodyâ€induced tissue injury. Journal of Pathology, 2012, 228, 8-19.	2.1	89
174	Pathogenicity of Autoantibodies in Anti-p200 Pemphigoid. PLoS ONE, 2012, 7, e41769.	1.1	44
175	Pathogenesis of Epidermolysis Bullosa Acquisita. Dermatologic Clinics, 2011, 29, 493-501.	1.0	27
176	Improvement of treatment-refractory atopic dermatitis by immunoadsorption: AÂpilot study. Journal of Allergy and Clinical Immunology, 2011, 127, 267-270.e6.	1.5	50
177	Rituximab for treatment-refractory pemphigus and pemphigoid: AÂcase series of 17 patients. Journal of the American Academy of Dermatology, 2011, 65, 552-558.	0.6	130
178	PI3KÎ² Plays a Critical Role in Neutrophil Activation by Immune Complexes. Science Signaling, 2011, 4, ra23.	1.6	130
179	Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets. Blood, 2011, 117, 6135-6142.	0.6	68
180	Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. British Journal of Dermatology, 2011, 164, 76-82.	1.4	77

#	Article	IF	Citations
181	The risk for cross-reactions after a cutaneous delayed-type hypersensitivity reaction to heparin preparations is independent of their molecular weight: a systematic review. Contact Dermatitis, 2011, 65, 187-194.	0.8	20
182	Generation of Antibodies of Distinct Subclasses and Specificity Is Linked to H2s in an Active Mouse Model of Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology, 2011, 131, 167-176.	0.3	63
183	Autoantibodyâ€induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita. Journal of Pathology, 2011, 224, 234-244.	2.1	39
184	Overexpression of the Flii gene increases dermalâ€“epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita. Journal of Pathology, 2011, 225, 401-413.	2.1	40
185	Complement-Fixing Anti-Type VII Collagen Antibodies Are Induced in Th1-Polarized Lymph Nodes of Epidermolysis Bullosa Acquisita-Susceptible Mice. Journal of Immunology, 2011, 187, 5043-5050.	0.4	50
186	Repetitive Immunization Breaks Tolerance to Type XVII Collagen and Leads to Bullous Pemphigoid in Mice. Journal of Immunology, 2011, 187, 1176-1183.	0.4	66
187	Work in progress: MiceNet: Monitoring behaviour of laboratory mice with sensor networks. , 2011, , .		1
188	Platelet Pâ€selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Experimental Dermatology, 2010, 19, 736-741.	1.4	56
189	High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases. Clinical Reviews in Allergy and Immunology, 2010, 38, 186-195.	2.9	53
190	Heparinâ€induced nonâ€necrotizing skin lesions: rarely associated with heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2010, 8, 1486-1491.	1.9	44
191	Animal models for autoimmune bullous dermatoses. Experimental Dermatology, 2010, 19, 2-11.	1.4	36
192	Constitutive and functionally relevant expression of JAM-C on platelets. Thrombosis and Haemostasis, 2010, 103, 857-859.	1.8	8
193	FcÎ³RIIA and FcÎ³RIIIB Are Required for Autoantibody-Induced Tissue Damage in Experimental Human Models of Bullous Pemphigoid. Journal of Investigative Dermatology, 2010, 130, 2841-2844.	0.3	48
194	Low Allergenic Potential With Fondaparinux: Results of a Prospective Investigation. Mayo Clinic Proceedings, 2010, 85, 913-919.	1.4	30
195	Pathogenicity of IgG subclass autoantibodies to type VII collagen: Induction of dermalâ€“epidermal separation. Journal of Autoimmunity, 2010, 34, 435-444.	3.0	55
196	Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita. British Journal of Dermatology, 2010, 162, 1064-1070.	1.4	22
197	Platelet, Not Endothelial, P-Selectin Expression Contributes to Generation of Immunity in Cutaneous Contact Hypersensitivity. American Journal of Pathology, 2010, 176, 1339-1345.	1.9	15
198	Need for an increasing awareness for heparin-induced skin lesions. Expert Review of Dermatology, 2010, 5, 1-3.	0.3	1

#	Article	IF	Citations
199	Shear Stressâ€“Mediated Adhesion of Acute Myeloid Leukemia and KG-1 Cells to Endothelial Cells Involves Functional P-Selectin. Stem Cells and Development, 2009, 18, 1235-1242.	1.1	9
200	Transcriptional induction of junctional adhesion molecule-C gene expression in activated T cells. Journal of Leukocyte Biology, 2009, 85, 796-803.	1.5	6
201	Therapeutic Use of Heparin beyond Anticoagulation. Current Drug Discovery Technologies, 2009, 6, 281-289.	0.6	90
202	Incidence and causes of heparin-induced skin lesions. Cmaj, 2009, 181, 477-481.	0.9	77
203	Junctional adhesion molecule (JAM)â€B supports lymphocyte rolling and adhesion through interaction with Î±4Î²1 integrin. Immunology, 2009, 128, 196-205.	2.0	39
204	PS3, A Semisynthetic Î²-1,3-Glucan Sulfate, Diminishes Contact Hypersensitivity Responses Through Inhibition of L- and P-Selectin Functions. Journal of Investigative Dermatology, 2009, 129, 1192-1202.	0.3	29
205	Computerâ€aided analysis of cell interactions under dynamic flow conditions. Experimental Dermatology, 2009, 18, 238-245.	1.4	5
206	Dimethylfumarate Reduces Leukocyte Rolling in Vivo through Modulation of Adhesion Molecule Expression. Journal of Investigative Dermatology, 2008, 128, 326-331.	0.3	65
207	Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 378-380.	1.3	18
208	The influence of heparinâ€™s molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims etÂal., Br J Dermatol 2007; 157:514â€“17. British Journal of Dermatology, 2008, 158, 849-851.	1.4	5
209	Topical 5-fluorouracil in Darier disease. British Journal of Dermatology, 2008, 158, 1393-1396.	1.4	19
210	C-terminally truncated kindlin-1 leads to abnormal adhesion and migration of keratinocytes. British Journal of Dermatology, 2008, 159, ???-???.	1.4	19
211	P-selectin. Expert Opinion on Therapeutic Targets, 2007, 11, 1103-1117.	1.5	80
212	Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. Haematologica, 2007, 92, 502-512.	1.7	34
213	How shingles can be beached. Lancet, The, 2007, 370, 1240.	6.3	1
214	Psoriasis and Risk of Myocardial Infarction. JAMA - Journal of the American Medical Association, 2007, 297, 361.	3.8	8
215	Diminished Lymphocyte Adhesion and Alleviation of Allergic Responses by Small-Molecule- or Antibody-Mediated Inhibition of L-Selectin Functions. Journal of Investigative Dermatology, 2007, 127, 90-97.	0.3	27
216	Oligonucleotides Suppress IL-8 in Skin Keratinocytes In Vitro and Offer Anti-Inflammatory Properties In Vivo. Journal of Investigative Dermatology, 2007, 127, 846-854.	0.3	25

#	Article	IF	Citations
217	Psoriasis: a possible risk factor for development of coronary artery calcification. British Journal of Dermatology, 2007, 156, 271-276.	1.4	326
218	Psoriasis patients show signs of insulin resistance. British Journal of Dermatology, 2007, 157, 1249-1251.	1.4	227
219	Persistence of peri-neural granulomas after successful treatment of leprosy. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 1414-1416.	1.3	3
220	Leprosy in a Pregnant Woman. Infection, 2007, 35, 37-39.	2.3	8
221	Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thrombosis and Haemostasis, 2006, 96, 611-617.	1.8	44
222	Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood, 2006, 108, 3938-3944.	0.6	500
223	The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thrombosis and Haemostasis, 2006, 95, 535-540.	1.8	98
224	Chronic venous insufficiency - a potential trigger for localized scleroderma. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 96-99.	1.3	11
225	Eukaryotic expression of the broad-spectrum chemokine receptor antagonist vMIP-II and its effects on T-cell function in vitro and in vivo. Experimental Dermatology, 2006, 15, 634-642.	1.4	12
226	SchÃ¶n et al. reply to â€œEfomycine M: an inhibitor of selectins?â€• Nature Medicine, 2006, 12, 873-874.	15.2	5
227	The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. Biochemical Pharmacology, 2006, 72, 474-485.	2.0	51
228	Structural Requirements of Heparin and Related Molecules to Exert a Multitude of Anti-Inflammatory Activities. Mini-Reviews in Medicinal Chemistry, 2006, 6, 1009-1023.	1.1	28
229	Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thrombosis and Haemostasis, 2006, 96, 611-7.	1.8	8
230	Complicated mycosis fungoides mimicking facial erysipelas. British Journal of Dermatology, 2005, 152, 1381-1383.	1.4	7
231	Eosinophilic cellulitis (Wells' syndrome) associated with colon carcinoma. Kolon-Karzinom assoziierte Eosinophile Zellulitis (Wells' Snydrom). JDDG - Journal of the German Society of Dermatology, 2005, 3, 530-531.	0.4	33
232	Junctional Adhesion Molecules (JAM)-B and -C Contribute to Leukocyte Extravasation to the Skin and Mediate Cutaneous Inflammation. Journal of Investigative Dermatology, 2005, 125, 969-976.	0.3	87
233	Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo. Experimental Dermatology, 2005, 14, 641-666.	1.4	31
234	Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thrombosis and Haemostasis, 2005, 94, 1265-1269.	1.8	53

#	Article	IF	Citations
235	Lymphocyte trafficking to inflamed skin â€“ molecular mechanisms and implications for therapeutic target molecules. Expert Opinion on Therapeutic Targets, 2005, 9, 225-243.	1.5	47
236	In vitro investigation on the selectin binding mechanisms in tumor cell metastasis and their inhibition by heparin. International Journal of Clinical Pharmacology and Therapeutics, 2005, 43, 570-572.	0.3	3
237	Endothelial P-Selectin as a Target of Heparin Action in Experimental Melanoma Lung Metastasis. Cancer Research, 2004, 64, 2743-2750.	0.4	186
238	Activated, Not Resting, Platelets Increase Leukocyte Rolling in Murine Skin Utilizing a Distinct Set of Adhesion Molecules. Journal of Investigative Dermatology, 2004, 122, 830-836.	0.3	117
239	Intolerance of fondaparinux in a patient allergic to heparins. Contact Dermatitis, 2004, 50, 383-384.	0.8	24
240	Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. Journal of the American Academy of Dermatology, 2004, 50, 734-739.	0.6	56
241	New Insight into the Transport Mechanism of Hydrated Hydroxide Ions in Water. ChemInform, 2003, 34, no.	0.1	0
242	New Insight into the Transport Mechanism of Hydrated Hydroxide Ions in Water. Angewandte Chemie - International Edition, 2003, 42, 258-260.	7.2	77
243	The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria. British Journal of Dermatology, 2003, 148, 604-606.	1.4	13
244	Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis, 2003, 49, 158-159.	0.8	46
245	Herpes simplex virus type 2-associated eosinophilic cellulitis (Wells' syndrome). Journal of the American Academy of Dermatology, 2003, 48, S60-S61.	0.6	32
246	Enchondroma. Clinical Nuclear Medicine, 2002, 27, 695-697.	0.7	21
247	Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. Transplantation, 2002, 74, 1631-1634.	0.5	63
248	Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration. British Journal of Clinical Pharmacology, 2002, 54, 535-539.	1.1	6
249	Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nature Medicine, 2002, 8, 366-372.	15.2	139
250	Enchondroma: a benign osseous lesion with high F-18 FDG uptake. Clinical Nuclear Medicine, 2002, 27, 695-7.	0.7	6
251	Kinetics and dose-response of photosensitivity in cream psoralen plus ultraviolet A photochemotherapy: comparative in vivo studies after topical application of three standard preparations. British Journal of Dermatology, 2001, 144, 991-995.	1.4	17
252	Chronic dermatophytosis in lamellar ichthyosis: relevance of a T-helper 2-type immune response to Trichophyton rubrum.. British Journal of Dermatology, 2001, 145, 518-521.	1.4	25

#	Article	IF	Citations
253	Macrophage and lymphocyte homing in experimental diabetes. Experimental and Clinical Endocrinology and Diabetes, 1999, 107, S102-S107.	0.6	1
254	In vivo microscopy of murine islets of Langerhans: increased adhesion of transferred lymphocytes to islets depends on macrophage-derived cytokines in a model of organ-specific insulitis. Immunology, 1999, 98, 111-115.	2.0	10
255	Lymphocyte transfer in streptozotocin-induced diabetes: adhesion of donor cells to islet endothelium. American Journal of Physiology - Endocrinology and Metabolism, 1998, 274, E928-E935.	1.8	4
256	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Frontiers in Medicine, 0, 9, .	1.2	51